GEN Exclusives

More »

GEN News Highlights

More »
Dec 7, 2006

AC Immune and Genentech Ink Alzheimer’s Research Agreement Worth Up to $300M

  • AC Immune and Genentech will work together to develop anti-beta-amyloid antibodies for Alzheimer’s and other human diseases, under an exclusive global license agreement and research collaboration . AC Immune has developed conformation-specific antibodies against beta-amyloid generated by its SupraAntigen™ technology.

    Under the terms of this agreement, Genentech will provide funding for a multiyear collaborative research program and will cover all development and clinical costs of the lead antibody and subsequent antibody candidates. Genentech will make an upfront payment with the potential for a total of over $300 million in payments upon successful completion of clinical and regulatory milestones. Upon commercialization of a product, Genentech will pay AC Immune royalties on net sales of AC Immune’s antibodies.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Connectomics Advocacy

How might connectomics maintain lasting support?